About ArcariosArcarios combines Benelux’ best science in the field of bone and joint biology and was founded as a merger of TR-therapeutics and Therosteon.
TR-therapeutics is a consortium between Tigenix NV, a leading biotech in regenerative medicine based in the Leuven area, the universities of Gent (UG), Leuven (KUL) and the centre for drug discovery (CD3). TR-therapeutics brings together knowledge and expertise in drug discovery in the field of osteoarthritis and developed the ChondroBOOST platform. The platform has been extensively validated through various industrial collaborations.
Therosteon BV is a spin-off from the Erasmus Medical Center in Rotterdam and has been working with the OsteoBlast technology platform, developed by its scientific founder Professor Hans van Leeuwen. The OsteoBlast platform raised many industrial collaborations and drug discovery programs.
Arcarios is developing a balanced pipeline of innovative products with disease modifying therapeutics for bone and joint diseases, covered by a broad portfolio of granted and pending patents.
Arcarios has offices in Hasselt (BE) and Rotterdam (NL) and employs 17 people.